UK Markets closed

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.40-0.24 (-4.26%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close5.64
Open5.79
Bid5.35 x 1100
Ask5.71 x 800
Day's range5.37 - 5.79
52-week range4.81 - 12.61
Volume455,262
Avg. volume2,255,519
Market cap392.325M
Beta (5Y monthly)0.85
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates

    AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

  • Reuters

    AC Immune says number of families affected by Alzheimer's could nearly triple by 2050

    Alzheimer's drug developer AC Immune expects the number of families to be affected by the degenerative disease could nearly triple by 2050 to 150 million, its CEO said in an interview with a German magazine. The company recently secured a multi-million investment from the main backers of German COVID-19 vaccine developer BioNTech while acquiring a possible Parkinson's disease vaccine. AC Immune's CEO Andrea Pfeifer, in an interview with German business magazine Wirtschaftswoche published in its online edition on Sunday, described Alzheimer's, a non-curable disease the origin of which is not known, as "a slow pandemic rolling towards the world".

  • Zacks

    Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

    AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.